Public Employees Retirement System of Ohio Has $8.97 Million Position in Avantor, Inc. (NYSE:AVTR)

Public Employees Retirement System of Ohio increased its position in shares of Avantor, Inc. (NYSE:AVTR) by 34.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 346,822 shares of the company’s stock after purchasing an additional 88,205 shares during the quarter. Public Employees Retirement System of Ohio owned approximately 0.05% of Avantor worth $8,972,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Canada Pension Plan Investment Board raised its stake in shares of Avantor by 6.8% in the second quarter. Canada Pension Plan Investment Board now owns 22,927,325 shares of the company’s stock worth $486,059,000 after acquiring an additional 1,463,695 shares during the last quarter. State Street Corp lifted its holdings in Avantor by 58.0% during the 3rd quarter. State Street Corp now owns 22,368,244 shares of the company’s stock worth $578,666,000 after buying an additional 8,206,695 shares in the last quarter. Janus Henderson Group PLC boosted its position in Avantor by 18.2% in the 3rd quarter. Janus Henderson Group PLC now owns 17,692,705 shares of the company’s stock valued at $457,710,000 after buying an additional 2,719,615 shares during the last quarter. 1832 Asset Management L.P. increased its stake in shares of Avantor by 1,634.9% in the 2nd quarter. 1832 Asset Management L.P. now owns 8,530,118 shares of the company’s stock valued at $180,839,000 after buying an additional 8,038,451 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Avantor by 653.0% during the third quarter. The Manufacturers Life Insurance Company now owns 6,174,736 shares of the company’s stock valued at $159,740,000 after acquiring an additional 5,354,678 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Barclays dropped their price objective on Avantor from $28.00 to $25.00 and set an “overweight” rating for the company in a report on Friday, October 25th. Wells Fargo & Company cut their price objective on shares of Avantor from $30.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday, October 28th. UBS Group lowered their target price on shares of Avantor from $30.00 to $29.00 and set a “buy” rating for the company in a report on Tuesday, October 8th. Robert W. Baird cut their price target on Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research note on Monday, October 28th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $34.00 price objective on shares of Avantor in a research note on Thursday, September 26th. Three investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, Avantor has a consensus rating of “Moderate Buy” and an average price target of $27.69.

Avantor Stock Performance

Shares of Avantor stock opened at $22.53 on Friday. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.06. The firm has a market cap of $15.33 billion, a price-to-earnings ratio of 48.98, a price-to-earnings-growth ratio of 2.59 and a beta of 1.29. Avantor, Inc. has a one year low of $19.59 and a one year high of $28.00. The stock’s 50-day moving average is $22.59 and its 200-day moving average is $23.55.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.